AMG Q1 2026 slides: lithium surge drives revenue, EBITDA faces comps

AMG reported Q1 2026 revenue of $446.1 million, up 15% year over year, with net income more than doubling to $12.2 million even as adjusted EBITDA fell 24% to $44.2 million on tough comparisons. Lithium revenue surged 89% and vanadium EBITDA jumped 60%, offsetting a sharp drop in antimony profitability; the company also reiterated 2026 EBITDA guidance of $210 million to $240 million and capex of $70 million to $90 million. Liquidity remains adequate at $403 million, though net debt rose to $580.8 million and operating cash flow was negative $31.3 million in the quarter.

Analysis

The market is likely underappreciating the option value in AMG’s mix shift: lithium is no longer just a narrative asset, it is becoming a margin lever precisely as shipment timing normalizes and spot pricing inflects. The second-order effect is that even modest operational execution at Bitterfeld can create disproportionate EPS torque over the next two quarters because the business is moving from project drag to cash generation while capex intensity rolls over.

The bigger hidden catalyst is vanadium/chrome exposure tied to defense and domestic supply-chain reshoring. The new U.S. chrome facility matters less for near-term revenue than for customer qualification and pricing power; once qualified, AMG can capture stickier aerospace/defense demand with lower import exposure, which should support a higher multiple than a pure commodity processor. That said, working-capital absorption and leverage are the real near-term gating items: if prices stay firm but inventory keeps expanding, equity upside can be delayed even while reported EBITDA improves.

Consensus may be too focused on the year-over-year EBITDA decline and missing that this is a transition quarter with multiple deferred catalysts landing in Q2-Q4. The bear case is not commodity prices rolling over immediately, but execution slippage: vessel constraints, delayed customer qualification, or a weaker engineering order conversion rate would force investors to re-rate the story as a capital-intensive industrial rather than a self-funded critical-materials compounder. In that scenario, the stock could give back a meaningful portion of its 12-month rerating even if headline prices stay constructive.

From a positioning lens, the setup favors a relative-value long in AMG versus more levered single-commodity lithium or antimony names, because AMG has multiple shots on goal and a built-in hedge across end markets. The cleanest catalyst window is the next 1-2 quarters, when delayed lithium shipments, peak tantalum, and facility commissioning can all converge; if that sequence misses, downside should appear quickly because the multiple already embeds a strong execution premium.

Key Decisions for Investors

• Long APCOF for 1-2 quarters into the Q2 print: favorably skewed if lithium shipments normalize and EBITDA re-accelerates; use a stop if working capital stays elevated and operating cash flow remains negative.
• Pair trade: long APCOF / short a single-commodity lithium producer for the next 3-6 months to express the view that diversified critical-materials exposure plus downstream processing deserves a premium as prices recover.
• Add to APCOF only on a pullback toward the high-20s/low-30s euro range; at current levels the stock already prices in execution, so the best risk/reward is buying weakness ahead of Bitterfeld qualification milestones.
• Watch the U.S. chrome facility as a medium-term catalyst: if customer qualification lands on schedule in June-July, consider a tactical add because defense/aerospace end-market visibility could justify multiple expansion.
• Avoid chasing the move via commodity beta alone; if lithium prices flatten or antimony normalizes further, prefer APCOF over upstream-only names because the downside is cushioned by vanadium, engineering backlog, and recycling optionality.